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AcetAminophen-induced liveR injuRy  
in expeRimentAl AnimAls And humAns
H. Jaeschke*
Pharmacology, Toxicology & Therapeutics, The University of 
Kansas Medical Center, Kansas City, Kansas
Summary: Acetaminophen (APAP) or paracetamol hepatotoxicity is 
the most frequent cause of acute liver failure in the United States and 
many European countries. Animal studies have shown that the small 
fraction of the dose that is metabolized by cytochrome P-450 enzymes 
leads to formation of a reactive metabolite (NAPQI), which can be 
conjugated with glutathione but also binds to proteins. Although 
protein adduct formation, especially in mitochondria, correlates with 
cell toxicity, it is insufficient to trigger cell death. Instead, the initial 
mitochondrial dysfunction causes oxidant stress, which induces activa-
tion of MAP kinases ultimately causing c-jun-N-terminal kinase (JNK) 
phosphorylation and translocation to the mitochondria where P-JNK 
amplifies the oxidant stress and peroxynitrite formation. The enhanced 
mitochondrial oxidant stress together with translocation of lysosomal 
iron causes the membrane permeability transition pore (MPT) opening, 
resulting in the collapse of the membrane potential and cessation of 
ATP synthesis. The MPT also leads to mitochondrial matrix swell-
ing, which causes the rupture of the outer membrane with release of 
endonuclease G and apoptosis-inducing factor and translocation to the 
nucleus, where these enzymes induce DNA fragmentation. The loss of 
mitochondrial function and the nuclear DNA fragmentation are key 
events in APAP-induced cell necrosis. The massive cell necrosis leads to 
the release of damage-associated molecular patterns, which, through 
activation of toll-like receptors on macrophages, trigger cytokine 
formation and leukocyte activation and recruitment. However, the 
preponderance of the experimental evidence suggests that this inflam-
matory response has limited effect on the injury but results in the 
preparation of the regenerative or repair phase.
Although there has been enormous progress in understanding 
mechanisms of APAP-induced liver injury in animals, the insight into 
the human pathophysiology is more limited. However, in both human 
hepatocytes and in overdose patients, there is emerging evidence for 
the formation of protein adducts, the central role of mitochondrial 
damage and nuclear DNA fragmentation in necrotic cell death, and 
the repair function of inflammatory cells.
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QuAntifying the impAct of neviRApine-
bAsed pRophylAxis stRAtegies to pRevent 
motheR-to-child tRAnsmission of hiv-1 
using the populAtion AppRoAch
C. Kloft*
Freie Universitaet Berlin, Berlin, Germany
Summary: In 2011, a total of 330,000 (280,000–390,000) children 
acquired HIV infections predominantly during pregnancy, delivery, 
or breastfeeding in Africa,1 emphasizing the urgent need of effec-
tive strategies to prevent mother-to-child transmission of HIV-1 
(PMTCT). Several medicines and dosing regimens have been sug-
gested as PMTCT. Studies about these prevention strategies suffer 
from several constraints: due to resource limitations and to ethical 
reasons, intensive sampling is not feasible, typically resulting in a 
very sparse data situation. Hence, concepts capable of dealing with 
these situations seem very attractive: Pharmacometrics as an emerg-
ing science based on a transdisciplinary approach bridging ideas of 
biology, pharmacology, clinical pharmacy and pharmacology, medi-
cine, mathematics, and statistics represents an attractive framework 
to understand drug–patient interactions for optimizing prevention or 
treatment strategies. In detail, pharmacokinetic/pharmacodynamic/
biomarker/disease modeling by the population approach aims to elu-
cidate the mechanism-based relationships between dose exposure/
response while incorporating knowledge of the patients and their 
disease.2
In the presentation, the population analysis approach, its ben-
efits, and limitations will be explained and illustrated by an inves-
tigation of a PMTCT program containing nevirapine (NVP).3 For 
NVP: (1) the developed integrated pharmacokinetic model after 
oral administration to pregnant women and their newborns as well 
as derived stratified dosing strategies for different newborns will 
be demonstrated; and (2) how these concentration–time profiles 
of NVP were integrated into a stochastic model of HIV dynam-
ics (including the viral cycle in host cells) and transmission. Based 
on the final model, HIV transmission rates were predicted for a 
2-year period after birth which excellently agreed with data from 
7 independent PMTCT trials. Moreover, new mechanistic insights 
into transplacental transmission as well as resistance were gained, 
both with respect to the underlying NVP concentration–time pro-
files in pregnant women/mothers and newborns. The framework 
developed contributes to improve and guide PMTCT strategies in 
NVP prophylaxis regimens and more importantly in antiretroviral 
combination regimens.
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the swiss model of compRehensive 
Antidote pRovision
H. Kupferschmidt*
Swiss Toxicological Information Centre, Associated Institute of 
the University of Zurich, Zurich, Switzerland
Summary: Antidotes for the treatment of human poisoning are 
rare but essential medicines. Their provision is a particular chal-
lenge because their availability is limited, and many products are not 
authorized by the government. Their distribution may need special 
logistic efforts, and their clinical use is difficult because physicians 
are often not familiar with the indications, ways of administration, 
specific precautions, and adverse effects. Therefore, the provision 
of antidotes requires specific expertise, which is usually present in 
poison center specialists.
In Switzerland, the supply of antidotes is standardized. The anti-
dotes are classified in 3 complementary assortments based on the fre-
quency of poisoning, the place of administration, and logistic criteria. 
There is a small decentralized assortment for high street pharmacies, 
an assortment for hospitals with emergency departments, and an 
assortment for regional centers specialized in antidote supply. In addi-
tion to these, there are a number of special assortments: the antidotes 
stocked in the Swiss Military Pharmacy and in specialized decon-
tamination hospitals for mass casualties, the antivenins for exotic 
snake bites (antivenin.ch), antidotes for radionuclides, and antidotes 
for prehospital emergency medical services (“Swiss ToxBox”). All 
assortments are described in the Swiss Antidotes List.
The antidote network is managed by a working group of hos-
pital pharmacists and staff of the STIC on behalf of the cantons. 
The group updates and publishes the Swiss Antidotes List annually 
(www.antidota.ch).
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the Risk–benefit RelAtionship  
As A moRAl compAss
M. Lievre*
Clinical pharmacology, Faculte de Medecine Lyon Est, Lyon, 
France
Summary: The re-evaluation of the benefit/risk balance of a medi-
cal product as negative often triggers a scandal. The public outrage 
focuses usually on drug companies, portrayed as cynical and greedy, 
and regulatory agencies, considered as incompetent. The agencies 
should have known! Curiously, the attention of the public focuses 
on efficacy only at the beginning of a product life and turns to a 
safety-first attitude later, when doubts arise. This illustrates a lack 
of appreciation of the risk/benefit balance concept in our society, 
although life is an everlasting risk/benefit game. Most people tend 
to consider the risk/benefit balance of a medication to be established 
once and for all at the time of registration. In fact, clinical develop-
ment favors the evaluation of efficacy, represented by well-defined, 
prospectively sought end points, assessed with sufficient power, with 
a predefined statistical risk. In contrast, safety assessment is based 
on the reporting of mostly unknown events, with a very low power 
and a high risk of multiplicity. Given these uncertainties, changes in 
the benefit/risk balance after some time of marketing are not surpris-
ing. Such changes may occur with increasing treatment duration or 
simply with accumulation of data. Once a safety problem has been 
identified, it is necessary to confront the newly discovered risk with 
the already-established benefit. This is relatively easy if the benefit 
was assessed on hard, clinically relevant end points. However, when 
the benefit was assessed on intermediary or surrogate end points, it 
does not weigh much against toxicity. In the case of pioglitazone, 
the decrease in HbA1C accepted as a proof of efficacy did not stand 
the comparison with a modest increase in the risk of bladder cancer 
for the French Agency, who suspended the drug marketing authori-
zation. The EMA and the FDA said the drug may prove useful for 
some patient populations, without defining them. This points to a 
lack of an evidence-based method of assessment of the benefit/risk 
balance. Finally, the understanding of the benefit/risk balance varies 
according to the disease. Cancer is a disease for which there is a high 
tolerance to safety issues. Some cancer treatments are approved that 
give a very small increase in survival at the expense of a tremendous 
increase in grade III to IV toxicity. While some patients may put a 
very high price on living a few weeks more, a favorable benefit/risk 
balance for many others is doubtful. In conclusion, the benefit/risk 
assessment may be improved by a more extensive use of clinically 
relevant, patient-centered efficacy end points, early use of pharma-
coepidemiologic studies in the risk-management plans, and modeling 
to refine the approach for subpopulations. An effort to educate the 
public about the risk/benefit issues is necessary, with more objective 
information in the prescribing information and patient leaflet.
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populAtion phARmAcogenetics And its 
impAct foR phARmAcovigilAnce
A. LLerena*
CICAB Clinical Research Centre, Extremadura University 
Hospital and Medical School, Badajoz, Extremadura, Spain
Summary: There is scientific evidence about the existence of intereth-
nic differences in the metabolism and response to some drugs. The 
guidelines and dosage recommendations are not necessarily the 
most appropriate/accurate for populations with different ethnic 
backgrounds. As a result, there appears to be patients who do not 
respond to standard pharmacologic treatments designed for other 
populations or who present adverse drug reactions. These pharma-
cologic therapeutic failures may be related to genetic differences in 
the drug metabolism or to other factors linked to the drug mechanism 
of action.
Genetic factors may underlie individual susceptibility to some 
types of adverse drug reactions (ADRs). The ability to identify indi-
viduals who are susceptible to ADRs has the potential to reduce 
the personal harm and economic costs of drug-related morbidity. 
Information from these efforts could be usefully exploited for bet-
ter disease management and for minimizing harms from ADRs. 
Information about ethnic specificity of ADR-genetic biomarkers 
may help to improve the pharmacovigilance strategies in a given 
population.
In sum, pharmacogenetic studies may help pharmacovigilance, 
adapting therapeutic recommendations to each country, based on the 
specific ethnic and cultural identities. This has represented the main 
goal of the RIBEF Pharmacogenetic Iberoamerican Network, which 
gathers investigators and clinicians from all over Latin America and 
some European countries. The RIBEF strategy claims the necessity of 
developing regional or local strategies to improve the pharmacologic 
treatment’s benefit/risk relationship by developing studies specifically 
in indigenous and Latino Mestizo populations. Population-oriented 
pharmacogenetics might enhance global drug use policy and phar-
macovigilance at country level according to the ethnical background 
and cultural specificity, and has a strong potential to improve drug 
use in populations neglected in clinical trials.
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